Industry News
Pharmaceutical Industry News
The approval came “months earlier…
The approval came "months earlier than anticipated," Pfizer's Chief Oncology Officer, Jeff Legos, Ph.D., said in a statement.
The FDA has opened an…
The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug.
Cosette had been attempting to…
Cosette had been attempting to invalidate its $430 million buyout of Australia's Mayne Pharma since May and has now seen its wish granted based on a national security concern from the Australian government.
Some four years into Jemperli’s…
Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio.
A Novo Nordisk challenge has…
A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against companies selling versions of its GLP-1 blockbuster.
The commercial effects of an…
The commercial effects of an emboldened anti-vaccine movement in the U.S. were evident in the third quarter as several companies reported declining vaccine sales.
Changes to a public health webpage…
Changes to a public health webpage undercut the medical community's consensus rebuke of childhood vaccines as a cause of autism. They were swiftly condemned by public health advocates and the Senate's top healthcare legislator.
In an effort to break even by…
In an effort to break even by 2028, mRNA specialist Moderna is laying out a three-year business strategy, highlighting promising avenues for growth and setting out a goal to lift revenue by up to 10%
A new report finds China supplies…
A new report finds China supplies many key pharmaceutical ingredients to the U.S. market. Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius Biotech scored FDA approval. And
Sun Pharma has launched an…
Sun Pharma has launched an eye-opening awareness push about a common—and commonly overlooked—complication of diabetes.
Pfizer and manufacturer Tris…
Pfizer and manufacturer Tris Pharma were accused in 2023 of previously providing ADHD med Quillivant through the Texas Medicaid program despite knowing that the drug failed quality control tests during production.
After months of back-and-forth…
After months of back-and-forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing option for the eye disease drug.
Cdymax Pharma has been slapped…
Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls.
New Gene-Editing Strategy Could Help Development of Treatments for Rare Diseases
Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases.
Bayer’s Hyrnuo is catching up to…
Bayer's Hyrnuo is catching up to Boehringer Ingelheim's rival Hernexeos with an accelerated approval to treat a rare tumor type in certain patients with non-small cell lung cancer.
With a $140 million investment,…
With a $140 million investment, Moderna will build a new facility at its manufacturing campus in Norwood, Massachusetts. The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA
Antheia is teaming up with…
Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.
Novartis expect the expansion in…
Novartis expect the expansion in North Carolina will add 700 new employees to its ranks. The manufacturing campus will span some 700,000 square feet between new and existing space, Novartis said.
Agios’ shares nosedived by 49%…
Agios’ shares nosedived by 49% on Wednesday morning after the company revealed mixed phase 3 results for Pyrukynd in sickle cell disease.
Two months after Celltrion bought…
Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade the plant.